argenx SE (NASDAQ:ARGX) Receives Average Recommendation of “Moderate Buy” from Analysts

argenx SE (NASDAQ:ARGX) has been assigned a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $547.74.

A number of equities research analysts have commented on ARGX shares. Morgan Stanley decreased their price objective on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a report on Tuesday, May 28th. Robert W. Baird upped their target price on shares of argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. JPMorgan Chase & Co. upped their target price on shares of argenx from $500.00 to $640.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “hold” rating to a “buy” rating in a research report on Thursday, July 25th. Finally, Truist Financial increased their price target on shares of argenx from $480.00 to $540.00 and gave the company a “buy” rating in a research report on Monday, July 22nd.

Institutional Trading of argenx

A number of institutional investors have recently added to or reduced their stakes in ARGX. Price T Rowe Associates Inc. MD lifted its holdings in argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after purchasing an additional 1,830,651 shares in the last quarter. Capital World Investors raised its holdings in shares of argenx by 37.0% in the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after acquiring an additional 530,181 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of argenx by 24.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after acquiring an additional 439,889 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of argenx by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after acquiring an additional 346,178 shares in the last quarter. Finally, Avoro Capital Advisors LLC raised its holdings in shares of argenx by 23.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 1,234,567 shares of the company’s stock valued at $469,666,000 after acquiring an additional 234,567 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of argenx stock opened at $529.06 on Friday. The firm has a market capitalization of $31.44 billion, a PE ratio of -93.47 and a beta of 0.62. The company’s fifty day moving average price is $508.53 and its two-hundred day moving average price is $430.04. argenx has a 52-week low of $327.73 and a 52-week high of $554.74.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. During the same quarter in the previous year, the firm posted ($1.69) EPS. Analysts predict that argenx will post -0.37 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.